Reviewing PAREXEL International (PRXL) & Crispr Therapeutics (CRSP)

PAREXEL International (NASDAQ: PRXL) and Crispr Therapeutics (NASDAQ:CRSP) are both biotechnology & medical research – nec companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.


This table compares PAREXEL International and Crispr Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PAREXEL International 4.62% 19.95% 5.29%
Crispr Therapeutics -466.58% -38.42% -25.26%

Analyst Ratings

This is a breakdown of recent ratings and price targets for PAREXEL International and Crispr Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PAREXEL International 1 5 2 0 2.13
Crispr Therapeutics 0 3 3 0 2.50

PAREXEL International currently has a consensus target price of $78.30, indicating a potential downside of 11.10%. Crispr Therapeutics has a consensus target price of $22.38, indicating a potential upside of 17.45%. Given Crispr Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Crispr Therapeutics is more favorable than PAREXEL International.

Valuation and Earnings

This table compares PAREXEL International and Crispr Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PAREXEL International N/A N/A N/A $2.05 42.97
Crispr Therapeutics $5.16 million 151.44 -$23.17 million ($1.32) -14.43

PAREXEL International has higher earnings, but lower revenue than Crispr Therapeutics. Crispr Therapeutics is trading at a lower price-to-earnings ratio than PAREXEL International, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

87.5% of PAREXEL International shares are owned by institutional investors. Comparatively, 24.6% of Crispr Therapeutics shares are owned by institutional investors. 2.9% of PAREXEL International shares are owned by insiders. Comparatively, 40.0% of Crispr Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PAREXEL International Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company’s PI segment provides information technology solutions.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

Receive News & Ratings for PAREXEL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International and related companies with's FREE daily email newsletter.

Leave a Reply